Showing results (51-60 of 6,269) with videos related to
Sort By:
Pageof 627
Diabetes, Obesity & Metabolism|October 30, 2010
The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in β-cellsR J Kaufman, S H Back, B Song, et al.Diabetes, Obesity & Metabolism|January 29, 2011
Inhibition of NADPH oxidase alleviates experimental diabetes-induced myocardial contractile dysfunctionN D Roe, D P Thomas, J RenDiabetes, Obesity & Metabolism|January 29, 2011
Insulin dose-response studies in severely insulin-resistant type 2 diabetes--evidence for effectiveness of very high insulin dosesU Kampmann, P Hoeyem, A Mengel, et al.Diabetes, Obesity & Metabolism|January 29, 2011
Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndromeP U Feig, S Shah, A Hermanowski-Vosatka, et al.Diabetes, Obesity & Metabolism|December 1, 2010
Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetesJ Z Dong, Y Shen, J Zhang, et al.Diabetes, Obesity & Metabolism|December 1, 2010
The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell functionS Yoshida, T Ohishi, T Matsui, et al.Diabetes, Obesity & Metabolism|December 1, 2010
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjectsS Kasichayanula, X Liu, W C Shyu, et al.Diabetes, Obesity & Metabolism|December 1, 2010
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trialsA Schweizer, S Dejager, J E Foley, et al.Diabetes, Obesity & Metabolism|December 1, 2010
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyM-R Taskinen, J Rosenstock, I Tamminen, et al.Diabetes, Obesity & Metabolism|December 1, 2010
Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interactionL Morrow, M Hompesch, H Guthrie, et al.Pageof 627